Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 Gelatin Capsule

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

GSK2110183 IR Tablet

GSK Clinical Trials

This study is being conducted to measure the relative bioavailability of the original gelatin capsule formulation and a new formulation, immediate release (IR) tablet of Afuresertib (GSK2110183). The study will be composed of Screening, Treatment, and Follow-up Periods. A subject's total time involved in the study will be approximately 9 weeks. The study will enroll approximately 18 healthy volunteers.

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers

PK parameters include: area under the plasma concentration-time curve from time zero to infinity (AUC \[0-infinity\]), area under the plasma concentration time curve from time zero to last time of quantifiable concentration (AUC \[0-t\]), maximum observed plasma concentration (Cmax), and time to Cmax (tmax).

AEs will be collected from the start of Study Treatment and until the Follow-up contact.

Laboratory parameters include: hematology, clinical chemistry and urinalysis.

Triplicate 12-lead ECGs will be collected at Screening; in each Dosing Period on Day 1 and Day 3 of Dosing Period; and at Follow-up.

Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.

PK parameters include: AUC (0 - infinity), AUC (0 - t), Cmax, and tmax.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib	NCT02040480	Cancer	GSK2110183 Gela... GSK2110183 IR T...	18 Years - 40 Years	GlaxoSmithKline
Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib	NCT02040480	Cancer	GSK2110183 Gela... GSK2110183 IR T...	18 Years - 40 Years	GlaxoSmithKline
Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib	NCT02040480	Cancer	GSK2110183 Gela... GSK2110183 IR T...	18 Years - 40 Years	GlaxoSmithKline

Spots Global Cancer Trial Database for gsk2110183 gelatin capsule